Get the Stockscreener App
35.90
4.09%
-1.53
After Hours:
35.97
0.07
+0.19%
Surmodics Inc stock is traded at $35.90, with a volume of 401.35K.
It is down -4.09% in the last 24 hours and up +20.83% over the past month.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
See More
Previous Close:
$37.43
Open:
$37.28
24h Volume:
401.35K
Relative Volume:
3.73
Market Cap:
$513.34M
Revenue:
$138.20M
Net Income/Loss:
$5.52M
P/E Ratio:
94.47
EPS:
0.38
Net Cash Flow:
$9.86M
1W Performance:
+12.01%
1M Performance:
+20.83%
6M Performance:
+5.46%
1Y Performance:
-13.29%
1-Day Range:
$35.55
$37.40
1-Week Range:
$31.84
$38.26
52-Week Range:
$26.00
$41.48
Surmodics Inc Stock (SRDX) Company Profile
Name
Surmodics Inc
Sector
Industry
Phone
(952) 500-7000
Address
9924 W 74TH ST, EDEN PRAIRIE, MN
Compare SRDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
35.90 | 535.22M | 138.20M | 5.52M | 9.86M | 0.38 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Upgrade | Lake Street | Hold → Buy |
| Jun-13-23 | Upgrade | Needham | Hold → Buy |
| Feb-13-23 | Downgrade | Needham | Buy → Hold |
| Jul-23-20 | Upgrade | Needham | Hold → Buy |
| Dec-11-19 | Downgrade | Needham | Buy → Hold |
| Nov-01-19 | Downgrade | Lake Street | Buy → Hold |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Lake Street | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Feb-21-19 | Reiterated | Needham | Buy |
| May-16-18 | Reiterated | Needham | Buy |
| Mar-01-18 | Upgrade | Sidoti | Neutral → Buy |
| Feb-28-18 | Reiterated | Lake Street | Buy |
| Feb-28-18 | Initiated | Needham | Buy |
| Jul-14-17 | Initiated | Lake Street | Buy |
| Nov-21-16 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Oct-06-16 | Downgrade | Sidoti | Buy → Neutral |
| May-03-16 | Reiterated | Barrington Research | Outperform |
| Aug-06-15 | Reiterated | Barrington Research | Outperform |
| Mar-27-15 | Initiated | Dougherty & Company | Buy |
| Feb-25-14 | Initiated | Laidlaw | Buy |
| Aug-01-13 | Upgrade | Feltl & Co. | Buy → Strong Buy |
| Nov-12-12 | Reiterated | Barrington Research | Outperform |
View All
Surmodics Inc Stock (SRDX) Latest News
Surmodics falls as parties, FTC ask for extension of briefing schedule - Seeking Alpha
Why is Surmodics Inc. stock attracting strong analyst attentionMarket Forecast Opportunities For Every Investor - jammulinksnews.com
How Efficient Is Surmodics Inc. at Controlling Operating CostsBuy Strategy Tracker with Growth Indicators - Newser
Is Surmodics Inc. stock a good hedge against inflationControlled Entry Strategy With Safety Analytics - Newser
how surmodics inc. stock performs during market volatilityWeekly Movement Forecast With Chart Signals - Newser
Is a relief rally coming for Surmodics Inc. holdersQuarterly Investment Outlook and Key Summary - Newser
Analyzing drawdowns of Surmodics Inc. with statistical toolsFree Stock Selection With High Accuracy - Newser
Surmodics Inc. stock trendline breakdownFree Stock Screener With Smart Filters - Newser
Is Surmodics Inc. stock a growth or value playFree Oversold Recovery Opportunity Stocks - Newser
Surmodics Inc. Shows Early Signs of Technical StrengthCommunity Shared Smart Money Signals Show Movement - metal.it
Full technical analysis of Surmodics Inc. stockInvestment Timeline and ROI Summary Report - Newser
How Surmodics Inc. stock performs during market volatilityInvestment Strategy Designed for Capital Protection - metal.it
What makes Surmodics Inc. stock price move sharplyFree Consistent Profit Pattern Recognition Tools - Newser
Uncovering the Potential of Surmodics, Inc (SRDX) Stock - investchronicle.com
Surmodics SRDX 2025Q3 Earnings Preview Upside Ahead on Robust Revenue Growth - AInvest
How does Surmodics Inc. generate profit in a changing economySkyrocketing profit margins - jammulinksnews.com
Why Surmodics Inc. stock attracts strong analyst attentionFree Risk Assessment Services - Newser
Key External Factors That Drive Surmodics Inc. Stock Price MovementsFree Access to Community - Newser
What drives Surmodics Inc. stock priceFree Market Dynamics Reports - PrintWeekIndia
GTCR proposes divestiture to US FTC in Surmodics case - MLex
Surmodics (SRDX) Shares Climb 12% Amid FTC Pre-Trial Hearing - GuruFocus
Surmodics jumps amid pre-trial hearing in FTC's suit to block sale to GTCR (SRDX:NASDAQ) - Seeking Alpha
Is Surmodics Inc. a good long term investmentUnprecedented profits - PrintWeekIndia
What analysts say about Surmodics Inc. stockDynamic investment opportunities - Autocar Professional
Surmodics Inc. Stock Analysis and ForecastHigh-octane gains - Autocar Professional
(SRDX) Trading Report - news.stocktradersdaily.com
Minne InnoSurmodics adds to med-device portfolio with $39.9M acquisition of Vetex Medical - The Business Journals
Surmodics Inc Stock (SRDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):